false
OasisLMS
Catalog
SCCM Resource Library
Personalized Immunotherapy Approaches in COVID-19
Personalized Immunotherapy Approaches in COVID-19
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this talk, the speaker discusses the immune response to SARS-CoV-2 and the current state of immunomodulatory therapy for COVID-19. They highlight the importance of looking at the whole picture and not focusing on one specific pathway when considering immunomodulation. They discuss the use of IL-6 blocking agents, such as tocilizumab and sarilumab, and IL-1 receptor antagonists, like anakinra, in treating the hyperinflammatory response in severe COVID-19 cases. They also mention the potential benefit of blocking GM-CSF and the use of personalized immunomodulation based on immune phenotype. The speaker emphasizes the need for randomized controlled trials to evaluate these therapies and the importance of finding the right patient for the right treatment at the right time. Overall, the talk highlights the dynamic nature of the immune response to SARS-CoV-2 and the potential for targeted immunomodulation in COVID-19 treatment.
Asset Subtitle
Immunology, Infection, 2023
Asset Caption
Type: two-hour concurrent | Immunomodulation in Critical Illness: A 2023 Update (SessionID 1161720)
Meta Tag
Content Type
Presentation
Knowledge Area
Immunology
Knowledge Area
Infection
Membership Level
Professional
Membership Level
Select
Tag
Immunology
Tag
COVID-19
Year
2023
Keywords
immune response
SARS-CoV-2
immunomodulatory therapy
IL-6 blocking agents
IL-1 receptor antagonists
personalized immunomodulation
×
Please select your language
1
English